How to Get Lantus in New Hampshire

What Is Insulin Glargine and Why New Hampshire Patients Need It

Insulin glargine is a long-acting basal insulin analog dosed once daily to control fasting blood glucose in adults and pediatric patients with type 1 or type 2 diabetes. The drug's flat pharmacokinetic profile, peaking minimally at 4 to 5 hours and lasting up to 24 hours, makes it the most widely prescribed basal insulin in the United States [1]. Lantus (Sanofi) was the original brand; biosimilar versions including Basaglar (Eli Lilly) and Rezvoglar are now FDA-approved [2].

In New Hampshire, roughly 103,000 adults live with diagnosed diabetes according to CDC surveillance data, representing approximately 10.3% of the adult population [3]. Inadequate basal insulin coverage drives preventable hospitalizations for diabetic ketoacidosis and hyperosmolar hyperglycemic state. The ORIGIN trial (N=12,537) demonstrated that early basal insulin targeting fasting plasma glucose of 5.3 mmol/L or less reduced incident diabetes by 28% versus standard care over a median 6.2 years [4]. Getting access to insulin glargine in New Hampshire is therefore a concrete clinical priority, not a bureaucratic formality.

New Hampshire follows the American Diabetes Association's Standards of Care, which state that "basal insulin alone is the most convenient initial insulin regimen and is associated with the least weight gain and hypoglycemia" [5]. The ADA recommends initiating basal insulin at 10 units per day or 0.1 to 0.2 units per kilogram per day, titrating by 2 units every 3 days to reach a fasting glucose target of 80 to 130 mg/dL [5].

Telehealth Prescribing of Lantus in New Hampshire

New Hampshire permits telehealth prescribing of non-controlled prescription drugs including insulin glargine. No separate in-person visit is required before a telehealth clinician can send a Lantus prescription to a New Hampshire pharmacy, provided the prescriber establishes a valid patient-provider relationship and conducts an appropriate clinical evaluation [6]. This was clarified under NH RSA 329:1-d and corresponding Board of Medicine guidance issued during and after the COVID-19 public health emergency.

A typical telehealth visit for Lantus initiation covers the following: a review of current hemoglobin A1c (target per ADA is <7% for most nonpregnant adults) [5], fasting glucose logs, current medications, kidney function (eGFR matters for dose safety), and body weight [7]. The clinician also screens for hypoglycemia unawareness, which affects an estimated 25% of people with type 1 diabetes and increases severe hypoglycemia risk sixfold [8].

The HealthRX clinical team uses the following decision framework for telehealth Lantus initiation in New Hampshire patients:

1. Confirm diabetes diagnosis (type 1 or type 2) with A1c, fasting glucose, or prior records.
2. Review eGFR. If eGFR is <30 mL/min/1.73 m², dose conservatively and increase monitoring frequency.
3. Assess hypoglycemia history. Two or more severe episodes in the past year warrants CGM co-prescription.
4. Calculate starting dose: 0.1 to 0.2 units/kg/day for type 2, or match total daily dose from prior basal regimen for transitions.
5. Confirm pharmacy location and insurance status before sending the prescription.
6. Schedule a 2-week follow-up to review glucose logs and titrate.

Most New Hampshire telehealth platforms can transmit a Lantus prescription to a local pharmacy within 1 to 3 business days of a completed visit.

Labs Required Before Starting Lantus in New Hampshire

Lab work is not legally required before a Lantus prescription is issued, but prescribers practicing within the standard of care will typically review recent results. The minimum reasonable baseline includes hemoglobin A1c, a comprehensive metabolic panel (to assess renal and hepatic function), and a fasting lipid panel if not done in the prior 12 months [5].

Kidney function is particularly relevant. Insulin clearance decreases as eGFR falls, raising hypoglycemia risk in chronic kidney disease. The National Kidney Foundation notes that patients with eGFR <30 mL/min/1.73 m² may need insulin dose reductions of 25 to 50% [9]. A serum creatinine and calculated eGFR, which is part of a standard comprehensive metabolic panel, is therefore clinically necessary before dose setting.

For patients transitioning from an oral-only regimen to basal insulin, the ADA recommends continuing metformin (if tolerated and eGFR allows) alongside insulin glargine to reduce total insulin requirements [5]. Clinicians commonly add metformin 500 mg twice daily with meals and adjust based on tolerance. This combination can reduce basal insulin requirements by 25 to 30% compared to insulin alone in type 2 diabetes [10].

Thyroid function testing (TSH) is not required specifically for Lantus but may be ordered if the patient has symptoms suggesting thyroid disease, since hypothyroidism can worsen insulin resistance and alter A1c interpretation [11].

Who Can Prescribe Lantus in New Hampshire

New Hampshire law authorizes the following licensed practitioners to prescribe insulin glargine:

• Medical doctors (MDs) licensed under RSA 329
• Doctors of osteopathy (DOs) licensed under RSA 329
• Advanced practice registered nurses (APRNs/NPs) with prescriptive authority under RSA 326-B:11
• Physician assistants (PAs) with prescriptive authority under RSA 328-D

New Hampshire APRNs operate under a collaborative practice agreement for the first two years of practice, after which full independent prescriptive authority applies. PAs require a supervising physician but may prescribe insulin glargine within that arrangement [12]. This means a telehealth platform staffed by a licensed New Hampshire NP can legally issue a Lantus prescription without requiring a supervising physician to co-sign in most practice settings after that initial two-year period.

The FDA's prescribing information for Lantus does not restrict prescriber type. It requires only that the prescribing clinician assess renal function, risk of hypoglycemia, and current insulin regimen prior to initiating therapy [2].

Prior Authorization for Lantus in New Hampshire

Most commercial insurance plans in New Hampshire require prior authorization (PA) before covering Lantus. This is because biosimilar basal insulins (Basaglar, Rezvoglar) are listed as preferred on many formularies, and Lantus is classified as non-preferred. PA approval for Lantus typically requires documentation of one or more of the following:

• Clinical failure or adverse reaction to a preferred biosimilar basal insulin
• Prescriber attestation that the brand formulation is medically necessary
• A1c above the plan's threshold (often above 8% or above 9%) confirming suboptimal control
• Diagnosis of type 1 diabetes with supporting clinical records

New Hampshire Medicaid (NH Healthy Families, Meridian, and WellSense plans) does not currently cover Lantus on its preferred drug list. Medicaid beneficiaries are generally directed to NPH insulin or biosimilar long-acting options. Patients with Medicaid who specifically require Lantus will need a PA citing medical necessity, and approval is not guaranteed [13].

For commercial PA submissions, the American Association of Clinical Endocrinology's 2022 consensus statement on insulin therapy notes that "formulary restrictions that mandate step therapy through biosimilar insulins before approving branded analogs may delay glycemic control and increase the risk of adverse outcomes in high-risk patients" [14]. This published statement can serve as supporting clinical literature in a PA appeal.

New Hampshire Pharmacy Options for Lantus

Insulin glargine is available at most retail pharmacy chains in New Hampshire, including CVS, Walgreens, Rite Aid, Hannaford, and Walmart pharmacies. Walmart pharmacies sell ReliOn brand insulin glargine (Rezvoglar biosimilar) for $72.88 per vial without a prescription in New Hampshire, as New Hampshire is one of the states that permits pharmacist dispensing of insulin without a prescription under emergency access provisions [15].

Brand-name Lantus without insurance costs approximately $280 to $300 per 10 mL vial (1,000 units) at New Hampshire retail pharmacies. Sanofi's Insulins Valyou Savings Program caps out-of-pocket costs at $99 per month for eligible uninsured or underinsured patients [16]. GoodRx and similar discount platforms may reduce cash-pay prices to $200 to $250 per vial at select NH pharmacies.

503A compounding pharmacies licensed in New Hampshire may also prepare insulin glargine formulations for patients with specific dose requirements (for example, diluted preparations for pediatric patients or patients requiring very low doses) [17]. A 503A pharmacy dispenses compounded medications based on an individual patient prescription; it differs from a 503B outsourcing facility that produces drugs in bulk. Patients should confirm that any compounding pharmacy filling their Lantus prescription holds a current New Hampshire Board of Pharmacy license before accepting a compounded product.

Mail-order pharmacy is a practical option for many New Hampshire residents, especially those in rural areas such as Coos County or Carroll County. Mark Cuban's Cost Plus Drugs currently lists insulin glargine at significantly reduced cost with home delivery available to New Hampshire addresses [18].

Transferring an Existing Lantus Prescription to New Hampshire

Transferring a Lantus prescription from another state to a New Hampshire pharmacy is straightforward for a refill but requires attention to several steps. A New Hampshire pharmacist can accept a transferred prescription from an out-of-state pharmacy for a non-controlled drug such as insulin glargine, provided the original prescriber is licensed to practice in the state where the prescription was written [19].

If the prescribing clinician is not licensed in New Hampshire, the transfer covers only the remaining authorized refills on the original prescription. Once those are exhausted, the patient needs a new prescription from a New Hampshire-licensed provider. A telehealth visit with an NH-licensed clinician resolves this quickly, typically within 1 to 3 business days.

Patients who have relocated permanently to New Hampshire should establish care with a local endocrinologist or primary care physician. Wait times for endocrinology in New Hampshire average 30 to 90 days at major health systems such as Dartmouth Health and Catholic Medical Center. Telehealth bridging prescriptions, written by NH-licensed providers, are a practical interim solution.

Dosing, Titration, and Safety Monitoring for Lantus

The standard starting dose of insulin glargine for type 2 diabetes is 10 units subcutaneously once daily, administered at the same time each day. For type 1 diabetes, the starting dose is typically 0.2 units/kg/day as the basal component, with bolus insulin covering meals [2]. The FDA-approved label does not mandate a specific injection time, but most clinical guidelines recommend bedtime or a consistent morning injection to minimize nocturnal hypoglycemia risk [5].

Titration follows the "2-2-2" rule endorsed by many diabetes educators: increase the dose by 2 units every 3 days if fasting glucose exceeds 130 mg/dL on 3 consecutive mornings, and reduce by 2 units if fasting glucose falls below 80 mg/dL on 3 consecutive mornings [5]. The INSIGHT trial (N=5,765 insulin-naive type 2 patients) confirmed that patient-led titration of insulin glargine using this algorithm was as effective as physician-led titration, with A1c reductions of 1.7% versus 1.6% at 24 weeks (P<0.001) [20].

Hypoglycemia is the primary safety concern. Severe hypoglycemia (glucose <54 mg/dL with cognitive impairment requiring assistance) occurred at a rate of 0.05 events per patient-year in the ORIGIN trial across the glargine arm versus 0.03 in standard care [4]. Patients should receive education on symptom recognition, fast-acting glucose (15 grams of rapid glucose, repeat in 15 minutes), and glucagon emergency kits. The FDA mandates that insulin glargine labeling include a boxed warning regarding hypoglycemia [2].

Storage requirements: unopened Lantus vials and pens should be refrigerated at 36 to 46 degrees Fahrenheit and are stable until the manufacturer's expiration date. After first use, vials may be stored at room temperature (below 77 degrees Fahrenheit) for up to 28 days [2]. New Hampshire's seasonal temperature extremes (summer highs above 90 degrees Fahrenheit in some regions, winter below-zero conditions) mean patients should never store insulin in a car glove compartment or exposed to freezing.

Cost Reduction Strategies Specific to New Hampshire Residents

Several concrete programs reduce Lantus costs for New Hampshire patients:

Sanofi Insulins Valyou Savings Program caps Lantus at $99 per month for commercially insured patients who are underinsured or uninsured [16]. Eligibility requires income verification. Application is completed at insulins.us.

The New Hampshire Prescription Drug Affordability Program (NH PDA), established under RSA 126-A:85, allows qualifying low-income residents to access a formulary of essential drugs at reduced cost through a state-administered rebate mechanism [13]. Insulin glargine biosimilars appear on the NH PDA list; brand Lantus is reviewed case by case.

Sanofi's Patient Assistance Program (Sanofi Patient Connection) provides free Lantus to uninsured patients meeting income thresholds (generally at or below 400% of the federal poverty level) [16]. Processing time runs 2 to 4 weeks.

NeedyMeds.org lists additional New Hampshire-specific patient assistance resources, including pharmaceutical manufacturer programs and local charitable clinics in Manchester, Nashua, and Concord that may provide insulin at no cost [18].

What to Expect at Your First HealthRX Telehealth Visit for Lantus

A HealthRX telehealth visit for insulin glargine initiation in New Hampshire runs approximately 20 to 30 minutes. The clinician will review your most recent A1c (ideally within 3 months), current medications, allergy history, and fasting glucose log. If you do not have recent labs, the clinician may order a standing lab order at a local Quest Diagnostics or LabCorp draw site in New Hampshire before issuing the prescription, or may issue a bridging prescription pending lab review.

Bring the following to your visit: photo ID, insurance card, pharmacy name and address, most recent lab results if available, current blood glucose meter readings, and a list of all current medications including supplements. The clinician will confirm your preferred injection site education needs and whether you require a sharps disposal solution. New Hampshire law permits pharmacy-based sharps collection for used insulin needles and pen tips under NH RSA 149-M:17.

After the visit, your prescription is electronically transmitted to your chosen New Hampshire pharmacy. Standard retail pharmacies fill insulin glargine within 1 to 4 hours of receiving the electronic prescription. If prior authorization is required, the HealthRX team initiates the PA on the same day, with most commercial plans responding within 72 hours.